NCHR Testimony on SABER-Bupivacaine for Post-Surgery Pain Relief

January 16, 2020. There is not good evidence that SABER-bupivacaine provides a meaningful benefit to patients, and certainly not proven that the benefits outweigh the possible risks.  Most important, the sponsor has not proven that this formulation of the drug works better or is safer than the opioid, bupivacaine. Bupivacaine itself has been on the market for decades, is available as a generic, and does not have these new safety concerns. Thus, there is no reason to approve this drug just to have “another tool” when there is no evidence that it is a better tool than currently available options.

Read More »

Written Statement to the First Selectman’s Capital Improvement Program’s Public Hearing Regarding Dangers of Artificial Turf

January 9, 2020. Officials in communities all over the country have been misled by artificial turf salespeople. They were erroneously told that these products are safe. But on the contrary, there is clear scientific evidence that these materials are potentially harmful. The only question is how harmful and how much exposure is likely to be harmful? We should not be willing to take such a risk. Our children deserve better.

Read More »